<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04704193</url>
  </required_header>
  <id_info>
    <org_study_id>2020P003422</org_study_id>
    <secondary_id>U01CA243695-01</secondary_id>
    <nct_id>NCT04704193</nct_id>
  </id_info>
  <brief_title>Development and Implementation of Electronic Decision Aids for Genetic Testing in Inherited Cancer Syndromes</brief_title>
  <official_title>Development and Implementation of Electronic Decision Aids for Genetic Testing in Inherited Cancer Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An electronic decision aid will be used to assist individuals in choosing a multi-gene panel&#xD;
      with their medical oncologist instead of a genetic counselor. A decision aid may facilitate&#xD;
      quality decisions around the selection of a specific multi-gene panel without a genetic&#xD;
      counselor. Upon completion of the decision aid, participants will be asked to indicate their&#xD;
      decision about whether to pursue genetic testing and which specific multi-gene panel to&#xD;
      pursue. A survey will then be administered to assess participants' opinions on the decision&#xD;
      aid.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participant satisfaction with how educational information is presented in the decision aid</measure>
    <time_frame>This outcome will be measured immediately following completion of the decision aid</time_frame>
    <description>Measured with 6 items on a questionnaire that asks participants to rate the way certain information is presented on the decision aid. Each item is rated on a scale of 1 to 4, with 1 being poor and 4 being excellent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total time spent on decision aid</measure>
    <time_frame>From the start of the decision aid to the completion of the decision aid</time_frame>
    <description>The total amount of minutes spent on the decision aid</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Genetic Testing</condition>
  <arm_group>
    <arm_group_label>Electronic Decision Aid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this arm will complete an electronic decision aid for genetic testing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey of Decision Aid</intervention_name>
    <description>The decision aid will be evaluated by a survey administered to those who have used the tool.</description>
    <arm_group_label>Electronic Decision Aid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (18 years of age or older)&#xD;
&#xD;
          -  Diagnosed with malignant ovarian tumor or malignant pancreatic adenocarcinoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Children (&lt;18 years of age)&#xD;
&#xD;
          -  Unable to complete surveys&#xD;
&#xD;
          -  Previous germline genetic testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel C Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel C Chung, MD</last_name>
    <phone>6177263544</phone>
    <email>chung.daniel@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ava Siegel</last_name>
    <phone>6177261355</phone>
    <email>asiegel2@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Daniel Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 7, 2021</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2021</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Daniel C Chung</investigator_full_name>
    <investigator_title>Daniel C Chung, MD; Director, High-Risk GI Cancer Clinic</investigator_title>
  </responsible_party>
  <keyword>Decision Aid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplastic Syndromes, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

